{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:58:11Z","timestamp":1790074691427,"version":"4.0.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":722,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment of delirium often includes haloperidol. Second-generation antipsychotics like olanzapine have emerged as an alternative with possibly fewer side effects. The aim of this multicenter, phase III, randomized clinical trial was to compare the efficacy and tolerability of olanzapine with haloperidol for the treatment of delirium in hospitalized patients with advanced cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Eligible adult patients (\u226518\u2009years) with advanced cancer and delirium (Delirium Rating Scale-Revised-98 [DRS-R-98] total score \u226517.75) were randomized 1:1 to receive either haloperidol or olanzapine (age-adjusted, titratable doses). Primary endpoint was delirium response rate (DRR), defined as number of patients with DRS-R-98 severity score &amp;lt;15.25 and \u22654.5 points reduction. Secondary endpoints included time to response (TTR), tolerability, and delirium-related distress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between January 2011 and June 2016, 98 patients were included in the intention-to-treat analysis. DRR was 45% (95% confidence interval [CI], 31\u201359) for olanzapine and 57% (95% CI, 43\u201371) for haloperidol (\u0394 DRR \u221212%; odds ratio [OR], 0.61; 95% CI, 0.2\u20131.4; p = .23). Mean TTR was 4.5\u2009days (95% CI, 3.2\u20135.9\u2009days) for olanzapine and 2.8\u2009days (95% CI, 1.9\u20133.7\u2009days; p = .18) for haloperidol. Grade \u22653 treatment-related adverse events occurred in 5 patients (10.2%) and 10 patients (20.4%) in the olanzapine and haloperidol arm, respectively. Distress rates were similar in both groups. The study was terminated early because of futility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Delirium treatment with olanzapine in hospitalized patients with advanced cancer did not result in improvement of DRR or TTR compared with haloperidol. Clinical trial identification number. NCT01539733. Dutch Trial Register. NTR2559.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0470","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T14:25:14Z","timestamp":1575469514000},"page":"e570-e577","source":"Crossref","is-referenced-by-count":20,"title":["Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial"],"prefix":"10.1093","volume":"25","author":[{"given":"Maurice J.D.L.","family":"van der Vorst","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth C.W.","family":"Neefjes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon S.A.","family":"Boddaert","sequence":"additional","affiliation":[{"name":"Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bea A.T.T.","family":"Verdegaal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart","family":"Beeker","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia C.C.","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Department of General Practice, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands"},{"name":"Academic Hospice Demeter, De Bilt, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aartjan T.F.","family":"Beekman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke A.","family":"Wilschut","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Berkhof","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W.A.","family":"Zuurmond","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands"},{"name":"Hospice Kuria, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk M.W.","family":"Verheul","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,8]]},"reference":[{"key":"2021122510214962400_R1","volume-title":"Delirium: Acute Confusional States in Palliative Medicine","author":"Caraceni","year":"2011","edition":"2nd ed."},{"key":"2021122510214962400_R2","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/0269216312457214","article-title":"Delirium prevalence, incidence, and implications for screening in specialist palliative care inpatient settings: A systematic review","volume":"27","author":"Hosie","year":"2013","journal-title":"Palliat Med"},{"key":"2021122510214962400_R3","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)","author":"American Psychiatric Association","year":"2013"},{"key":"2021122510214962400_R4","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/1097-0142(20000901)89:5<1145::AID-CNCR24>3.0.CO;2-X","article-title":"Impact of delirium on the short-term prognosis of advanced cancer patients","volume":"89","author":"Caraceni","year":"2000","journal-title":"Cancer"},{"key":"2021122510214962400_R5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrclinonc.2014.147","article-title":"Delirium in patients with cancer: Assessment, impact, mechanisms and management","volume":"12","author":"Lawlor","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122510214962400_R6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1176\/appi.psy.43.3.183","article-title":"The delirium experience: Delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses\/caregivers, and their nurses","volume":"43","author":"Breitbart","year":"2002","journal-title":"Psychosomatics"},{"key":"2021122510214962400_R7","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.24215","article-title":"Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers","volume":"115","author":"Bruera","year":"2009","journal-title":"Cancer"},{"issue":"suppl 4","key":"2021122510214962400_R8","doi-asserted-by":"crossref","first-page":"iv143","DOI":"10.1093\/annonc\/mdy147","article-title":"Delirium in adult cancer patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Bush","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122510214962400_R9","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005594.pub3","article-title":"Antipsychotics for treatment of delirium in hospitalized non-ICU patients","author":"Burry","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122510214962400_R10","author":"National Clinical Guideline Centre"},{"key":"2021122510214962400_R11","author":"National Comprehensive Cancer Network"},{"key":"2021122510214962400_R12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp-2015-311049","article-title":"Antipsychotic medications for the treatment of delirium: A systematic review and meta-analysis of randomised controlled trials","volume":"87","author":"Kishi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021122510214962400_R13","first-page":"345","article-title":"An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients","volume":"19","author":"Lin","year":"2008","journal-title":"J Int Med Taiwan"},{"key":"2021122510214962400_R14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/DDDT.S45575","article-title":"Quetiapine versus haloperidol in the treatment of delirium: A double-blind, randomized, controlled trial","volume":"24","author":"Maneeton","year":"2013","journal-title":"Drug Des Devel Ther."},{"key":"2021122510214962400_R15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamainternmed.2016.7491","article-title":"Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: A randomized clinical trial","volume":"177","author":"Agar","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2021122510214962400_R16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1891\/rtnp.17.1.31.53169","article-title":"The Delirium Observation Screening Scale: A screening instrument for delirium","volume":"17","author":"Schuurmans","year":"2003","journal-title":"Res Theory Nurs Pract"},{"key":"2021122510214962400_R17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12885-019-5351-8","article-title":"Accuracy of the Delirium Observational Screening Scale (DOS) as a screening tool for delirium in patients with advanced cancer","volume":"19","author":"Neefjes","year":"2019","journal-title":"BMC Cancer"},{"key":"2021122510214962400_R18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1176\/jnp.13.2.229","article-title":"Validation of the Delirium Rating Scale-revised-98: Comparison with the delirium rating scale and the cognitive test for delirium","volume":"13","author":"Trzepacz","year":"2001","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2021122510214962400_R19","author":"CTCAE"},{"key":"2021122510214962400_R20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1176\/appi.psy.43.3.175","article-title":"An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients","volume":"43","author":"Breitbart","year":"2002","journal-title":"Psychosomatics"},{"key":"2021122510214962400_R21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1208\/s12248-013-9540-0","article-title":"Futility rules in bioequivalence trials with sequential designs","volume":"16","author":"Fuglsang","year":"2014","journal-title":"AAPS J"},{"key":"2021122510214962400_R22","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/cam4.1106","article-title":"Identification of patients with cancer with a high risk to develop delirium","volume":"6","author":"Neefjes","year":"2017","journal-title":"Cancer Med"},{"key":"2021122510214962400_R23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0163-8343(03)00070-7","article-title":"Risk factors for development of delirium among oncology patients","volume":"25","author":"Ljubisavljevic","year":"2003","journal-title":"Gen Hosp Psychiatry"},{"key":"2021122510214962400_R24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/ageing\/aft148","article-title":"New horizons in the pathogenesis, assessment and management of delirium","volume":"42","author":"Maclullich","year":"2013","journal-title":"Age Ageing"},{"key":"2021122510214962400_R25","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/gps.4823","article-title":"Delirium pathophysiology: An updated hypothesis of the etiology of acute brain failure","volume":"33","author":"Maldonado","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"2021122510214962400_R26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/hup.1117","article-title":"Risperidone versus olanzapine for the treatment of delirium","volume":"25","author":"Kim","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"2021122510214962400_R27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jama.2017.11468","article-title":"Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: A randomized clinical trial","volume":"318","author":"Hui","year":"2017","journal-title":"JAMA"},{"key":"2021122510214962400_R28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/SPC.0000000000000236","article-title":"Neuroleptics in the management of delirium in patients with advanced cancer","author":"Hui","year":"2016","journal-title":"Curr Opin Support Palliat Care"},{"key":"2021122510214962400_R29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","article-title":"Antipsychotic drug use and mortality in older adults with dementia","volume":"146","author":"Gill","year":"2007","journal-title":"Ann Intern Med"},{"key":"2021122510214962400_R30","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs. atypical antipsychotic medications","volume":"353","author":"Wang","year":"2005","journal-title":"N Engl J Med"},{"key":"2021122510214962400_R31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: Number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"2021122510214962400_R32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1471-244X-13-240","article-title":"Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium","volume":"13","author":"Yoon","year":"2013","journal-title":"BMC Psychiatry"},{"key":"2021122510214962400_R33","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/gps.4759","article-title":"Debate article: Antipsychotic medications are clinically useful for the treatment of delirium","volume":"33","author":"Meagher","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"2021122510214962400_R34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"2021122510214962400_R35","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001568","article-title":"Antipsychotic drugs and the risk of ventricular arrhythmia and\/or sudden cardiac death: A nation-wide case-crossover study","volume":"4","author":"Wu","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2021122510214962400_R36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122510214962400_R37","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/gps.3900","article-title":"The delirium experience: What is the effect on patients, relatives and staff and what can be done to modify this?","volume":"28","author":"Partridge","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"2021122510214962400_R38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/NUR.0b013e3181ee5f95","article-title":"Nursing identification of delirium","volume":"24","author":"Flagg","year":"2010","journal-title":"Clin Nurse Spec"},{"key":"2021122510214962400_R39","first-page":"1697","article-title":"The Hospital Elder Life Program: A model of care to prevent cognitive and functional decline in older hospitalized patients","volume":"48","author":"Inouye","year":"2000","journal-title":"Hospital Elder Life Program. J Am Geriatr Soc"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0470","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0470","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/3\/e570\/41920497\/oncolo_25_3_e570.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/3\/e570\/41920497\/oncolo_25_3_e570.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T05:22:25Z","timestamp":1640409745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/3\/e570\/6443403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,8]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,12,8]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0470","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3,1]]},"published":{"date-parts":[[2019,12,8]]}}}